Baili Tianheng: Approval for clinical trials of BL-M14D1 combination therapy for extensive-stage small cell lung cancer.

On June 14th, Bailingtianheng announced that the company has recently received the official approval letter for the clinical trial of the innovative biopharmaceutical BL-M14D1, developed independently by the company, from the National Medical Products Administration. The clinical trial for the combination therapy of BL-M14D1 has been approved, allowing the drug to be used in combination with PD-1/PD-L1 monoclonal antibodies anti-angiogenic drugs chemotherapy for the treatment of extensive-stage small cell lung cancer.